Expertise in
21
conditions

Dr. Ranveer K. Nand

Hematology
Ascension Columbia St. Mary's Hospital-Ozaukee Polly And Bill Van Dyke Cancer Center
13111 N Port Washington Rd, 
Thiensville, WI 
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Expertise in
21
conditions
Ascension Columbia St. Mary's Hospital-Ozaukee Polly And Bill Van Dyke Cancer Center
13111 N Port Washington Rd, 
Thiensville, WI 

Overview

Ranveer Nand is a Hematologist practicing medicine in Thiensville, Wisconsin.

Dr. Nand is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Immune Thrombocytopenic Purpura (ITP), Adult Immune Thrombocytopenia, and Hemangioma Thrombocytopenia Syndrome.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 29 clinical trials. Dr. Nand is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in WI

Hospital Affiliations

Ascension Columbia St Marys Hospital Milwaukee
Orthopaedic Hospital Of Wisconsin
Aurora Medical Center
Ascension Se Wisconsin Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Children's Community Health
  • EPO
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Common Ground Healthcare Cooperative
  • EPO
  • PPO
Dean Health
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Network Health
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Ascension Columbia St. Mary's Hospital-Ozaukee Polly And Bill Van Dyke Cancer Center
13111 N Port Washington Rd, Thiensville, WI 53097

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

29 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
Enrollment Status: Recruiting
Publish Date: September 02, 2026
Intervention Type: Procedure, Other
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Drug
Study Drugs: Endoxifen Hydrochloride, Tamoxifen Citrate
Study Phase: Phase 2
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
View 8 Less Clinical Trials

1 Total Publications

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 29, 2023
Similar Doctors
Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

Froedtert And The Medical College Of Wisconsin Froedtert Hospital

9200 W Wisconsin Ave, 
Milwaukee, WI 
 (15.7 miles away)
414-805-3666
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Timothy Fenske is a Hematologist practicing medicine in Milwaukee, Wisconsin. Dr. Fenske is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Fenske is currently accepting new patients.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Froedtert Hospital

900 N. 92nd St., 
Milwaukee, WI 
 (15.8 miles away)
414-805-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Joshua Field is an Associate Medical Director at the Versiti Blood Center of Wisconsin and an Assistant Professor of Medicine at the Medical College of Wisconsin. Dr. Field specializes in the treatment of sickle cell disease and other benign hematological disorders at Froedtert Hospital and Children’s Hospital of Wisconsin. Dr. Field graduated from the University of Iowa Medical School. He completed an Internal Medicine Residency and Fellowships in Hematology and Transfusion Medicine at Washington University in St. Louis, where he was Chief Resident in Internal Medicine and Chief Fellow in Hematology/Oncology. Dr. Field is Board Certified in Internal Medicine and Hematology. Dr. Field is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Hemoglobinopathy, Hemolytic Anemia, Congenital Hemolytic Anemia, and Bone Marrow Aspiration. Dr. Field is board certified in Hematology and Internal Medicine. Dr. Field is currently accepting new patients.

Expertise in
15
conditions
Dr. Anita B. D'souza
Hematology | Oncology
Expertise in
15
conditions
Dr. Anita B. D'souza
Hematology | Oncology
Referral may be required

Clinical Cancer Center - Froedtert Hospital

8800 W. Doyne Ave., 
Milwaukee, WI 
 (15.7 miles away)
414-805-0505
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Anita D’Souza is a professor of medicine (hematology/oncology). She completed her medical school from Goa Medical College, India where she graduated at the top of her class and was awarded Best Medical Graduate. She completed her internal medicine residency from William Beaumont Hospital in Michigan where she received the Zimmerman Award for Outstanding Clinical Judgment, Leadership, and Integrity. She completed her hematology/oncology fellowship from the Mayo Clinic in Rochester, Minnesota. She is a past recipient of the Daniel McCarty Award for Research Excellent and Women in Science Rising Pioneer Award at MCW. Dr. D'souza is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Multiple Myeloma, Primary Amyloidosis, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Tissue Biopsy. Dr. D'souza is board certified in Medical Oncology And Hematology and Internal Medicine. Dr. D'souza is currently accepting new patients.

Frequently Asked Questions about Dr. Ranveer K. Nand

How do I make an appointment with Dr. Ranveer K. Nand?

You can book an appointment with Dr. Ranveer K. Nand by calling their office at 262-243-7454. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ranveer K. Nand a top-rated expert for Chronic Lymphocytic Leukemia (CLL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ranveer K. Nand is classified as an Distinguished expert for Chronic Lymphocytic Leukemia (CLL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ranveer K. Nand specialize in?

While Dr. Ranveer K. Nand is a Hematology, they have specific expertise in Chronic Lymphocytic Leukemia (CLL), Immune Thrombocytopenic Purpura (ITP), and Adult Immune Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ranveer K. Nand participate in research or clinical trials?

Yes. Dr. Ranveer K. Nand has published 1 articles and abstracts on conditions like Chronic Lymphocytic Leukemia (CLL). You can view a list of Dr. Ranveer K. Nand's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ranveer K. Nand accept my insurance?

Dr. Ranveer K. Nand accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 262-243-7454 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nand's expertise for a condition
ConditionClose
    View All 20 Advanced Conditions
    View All 48 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile